Vilon Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Vilon?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Epigenetic aging, immune system restoration, tumor prevention, cardiovascular gene expression, radiation recovery
• First Synthesized: 1970s, as part of Professor Vladimir Khavinson’s Soviet-era peptide bioregulator program
• Molecular Weight: 275.30 g/mol
• Research Status: Over four decades of published research, predominantly preclinical; human data limited to in vitro studies on elderly donor cells
• Key Mechanisms: Chromatin deheterochromatinization, ribosomal gene reactivation, interleukin-2 upregulation, tyrosine kinase signaling modulation
• Published Studies: Hundreds of publications, primarily in Russian-language journals; limited English-language peer-reviewed literature
• Clinical Trial Status: No registered human clinical trials identified; human cell studies conducted in vitro
• Regulatory Classification: Research use only; not approved for human therapeutic application in any major jurisdiction

What is Vilon?

Vilon is a synthetic dipeptide composed of two amino acids: lysine (Lys) and glutamic acid (Glu), linked in sequence as Lys-Glu. With a molecular weight of just 275.30 g/mol, it holds the distinction of being among the shortest known biologically active peptides — two amino acids producing measurable effects across multiple organ systems in research models.

The peptide originated from the systematic research program of Professor Vladimir Khavinson, a Soviet and later Russian scientist whose work beginning in the 1970s aimed to identify the minimal functional sequences within tissue-derived peptide extracts. Khavinson’s team analyzed thymus tissue to determine which short amino acid sequences retained the biological activity of longer thymic peptides. Vilon emerged as one of more than 20 distinct peptide bioregulators developed through this methodology. The research program had early connections to Soviet military interests in protecting personnel from environmental stressors, particularly radiation exposure, before evolving into a broader investigation of aging, immunity, and gene regulation.

What makes Vilon scientifically unusual is its proposed mechanism. Most bioactive peptides work by binding to cell surface receptors, triggering downstream signaling cascades. Vilon’s primary mechanism appears to operate differently, at the level of chromatin, the complex of DNA and proteins that controls which genes are accessible for transcription. As organisms age, certain genes become progressively silenced through tightening of chromatin structure. Vilon research investigates whether the peptide can reverse this silencing in a selective and controlled way.

The research base for Vilon spans over four decades, but it comes with important caveats. The overwhelming majority of publications originate from Russian-language literature and from Khavinson’s own research group. No human clinical trials have been registered or published. Human data consists primarily of in vitro experiments on cultured lymphocytes taken from elderly donors. Researchers approaching this literature should weigh both the breadth of preclinical investigation and the significant gaps in independent replication and human evidence.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Vilon’s structure pairs a positively charged lysine residue with a negatively charged glutamic acid residue. This combination creates an amphipathic molecule, one that carries both positive and negative charge regions. Researchers hypothesize this amphipathic character facilitates interactions with cell membranes and enables nuclear localization, which would be necessary for a peptide acting directly on chromatin.

The compact two-amino-acid structure confers exceptional enzymatic stability relative to longer peptides. Larger peptides are typically susceptible to rapid degradation by circulating proteases and digestive enzymes. The brevity of Vilon’s sequence limits the number of peptide bonds available for enzymatic cleavage, contributing to its reported stability in acidic environments including gastric conditions.

This structural simplicity also creates research challenges. The minimal size means fewer distinguishing chemical features, making it difficult to design binding assays or imaging probes that track Vilon in living tissue without chemical modification that might alter its behavior. These practical constraints contribute to the mechanistic gaps discussed in later sections.

Mechanisms of Action Being Investigated

Vilon’s proposed mechanisms center on epigenetic regulation rather than conventional receptor pharmacology. No specific membrane receptor for Vilon has been identified in published literature. The working model positions Vilon as a chromatin-interacting molecule that modulates gene accessibility, with downstream effects on immune function, cellular metabolism, and gene expression patterns.

Chromatin Deheterochromatinization and Gene Reactivation

The central mechanism investigated for Vilon involves structural changes to facultative heterochromatin. Chromatin exists in two primary states: euchromatin, which is loosely organized and transcriptionally active, and heterochromatin, which is tightly condensed and transcriptionally silent. Facultative heterochromatin represents genes that are silenced conditionally, as opposed to permanently silenced structural heterochromatin. Aging progressively expands facultative heterochromatin, silencing genes that should remain active in healthy adult cells.

Vilon treatment in cultured lymphocytes from elderly donors produced chromatin heat absorption patterns, measured by differential scanning microcalorimetry, that resembled patterns seen in younger donor cells [1,2]. This observation suggests structural decondensation of tightly packed chromatin regions. Researchers interpret this as restoration of a more youthful chromatin architecture, with previously silenced genes becoming transcriptionally accessible.

Critically, this decondensation appears selective. Vilon targets facultative heterochromatin but does not appear to affect pericentromeric structural heterochromatin, which is essential for chromosome stability [1]. Indiscriminate chromatin opening would be expected to destabilize the genome; the apparent selectivity is considered a defining and important feature of Vilon’s proposed mechanism.

Ribosomal Gene Reactivation Through Nucleolus Organizer Regions

A specific chromatin target studied in Vilon research is the nucleolus organizer region (NOR). NORs are chromosomal segments containing the ribosomal RNA genes, which encode the structural components of ribosomes. Ribosomal biogenesis, the production of new ribosomes, depends on active NOR transcription. Age-related heterochromatinization silences NOR regions, reducing ribosomal production capacity in aging cells and impairing protein synthesis.

Vilon treatment reactivated ribosomal genes silenced by age-related chromatin condensation in elderly donor lymphocytes [2]. The result was enhanced synthetic capacity in aged immune cells. This finding connects Vilon’s epigenetic mechanism directly to a functional cellular outcome: restoration of protein production machinery that declines with age.

Immune Cell Signaling and Interleukin-2 Upregulation

Beyond chromatin remodeling, Vilon modulates specific immune signaling pathways. Studies in splenocytes demonstrated enhanced interleukin-2 (IL-2) gene expression following Vilon treatment [3]. IL-2 is a central cytokine for T-cell proliferation and immune activation. Reduced IL-2 production is a hallmark of immunosenescence, the age-related decline in immune function.

Vilon also increases expression of HLA-DR and CD54 surface markers on thymic cells, both of which indicate activated immune function. CD5 marker expression increased by 78% in thymic cells in one study, associated with differentiation toward CD4-positive T-helper cell lineages [4]. These findings position Vilon as an immune activator operating through gene expression rather than direct receptor stimulation.

Anti-inflammatory effects have also been reported. Cells exposed to inflammatory stimuli showed reduced levels of tumor necrosis factor-alpha and interleukin-6 following Vilon treatment, suggesting the peptide modulates immune activation bidirectionally depending on the cellular state [4].

Cell Proliferation Signaling and Kinase Modulation

Vilon affects intracellular signaling cascades associated with proliferation. Studies report increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases, enhanced ERK1/2 phosphorylation in certain cell types, and elevation of intracellular calcium concentrations in thymocytes and macrophages [4]. Calcium signaling is a critical early step in immune cell activation. These proliferative signals are balanced by reported pro-apoptotic effects in tissue culture models, suggesting Vilon promotes cell renewal rather than unchecked expansion.

Antioxidant and Cytoprotective Activity

Vilon treatment reduced lipid peroxidation markers in aging cell models, suggesting a protective effect against oxidative damage. Lipid peroxidation damages cell membranes and contributes to age-related cellular decline. Supporting evidence includes reported protective effects on mitochondrial function in aged tissues and maintenance of cellular redox balance under stress conditions [4].

Mechanistic Gaps

The precise molecular targets through which Vilon interacts with chromatin have not been resolved at atomic resolution. Whether the peptide binds directly to DNA, interacts with histone proteins, or engages chromatin-remodeling enzyme complexes remains unknown. How a peptide with a presumed short plasma half-life produces biological effects lasting days to weeks is unexplained. Tissue-specific selectivity mechanisms have not been elucidated, and the contribution of metabolic breakdown products to observed effects is unknown.

Major Areas of Research

Vilon research spans several biological domains, with the most developed literature addressing aging, immunity, and tumor prevention. Each area summarized below reflects the scope and current state of preclinical investigation.

Aging and Lifespan Research

Aging biology represents Vilon’s most extensively studied research application. Female CBA mice treated with subcutaneous Vilon from six months of age showed increased mean lifespan compared to untreated controls. Treated animals also showed enhanced physical activity and endurance, decreased core body temperature (associated in aging research with reduced metabolic rate and extended lifespan), and reduced incidence of spontaneous neoplasms [6,7].

In vitro studies on human cells from elderly donors provided the most directly translatable findings. Cultured lymphocytes from older individuals showed progressive accumulation of facultative heterochromatin compared to younger donor cells. Vilon treatment reversed this pattern, restoring chromatin organization more consistent with younger cell populations and reactivating ribosomal genes silenced by age-related condensation [1,2,8].

Key Research Highlights:

• Increased mean lifespan in female CBA mice with subcutaneous administration
• Chromatin architecture in elderly donor lymphocytes shifted toward younger patterns after treatment
• Ribosomal gene reactivation demonstrated in aged human immune cells
• Enhanced physical endurance without adverse effects on estrous function in animal models

Immunology and Immune Restoration Research

Immune research investigates Vilon’s effects both in healthy aging models and in immunocompromised states following radiation exposure or stress. Post-irradiation, treated rats showed accelerated recovery of thymus architecture, with restoration of thymic lobule structure through expansion of cortical layers and enhanced thymocyte proliferation and differentiation [12].

Normalized lymphocyte counts, increased granulocyte levels, and improved maturation of both B-cell and T-cell populations were observed in irradiated animal models. These effects connect directly to Vilon’s proposed chromatin mechanism: reactivating immune-related genes silenced by radiation damage restores the transcriptional programs needed for immune cell renewal.

In vitro work confirmed activation of neutrophils and macrophages at specific concentrations, along with lymphocyte redistribution in lymphoid organs. The 78% increase in CD5 marker expression on thymic cells supports a role in T-helper cell differentiation [4,12].

Key Research Highlights:

• Accelerated thymic recovery following gamma-irradiation in rat models
• Normalized lymphocyte counts and enhanced B-cell and T-cell maturation post-irradiation
• Enhanced interleukin-2 gene expression in splenocytes
• Macrophage and neutrophil activation at specific concentrations in vitro

Oncology and Tumor Prevention Research

Tumor prevention studies are among the most striking in the Vilon literature, though they require careful interpretation. In aging mice, Vilon treatment reduced spontaneous tumor incidence, with decreases in both pulmonary adenomas and mammary adenocarcinomas compared to untreated controls [9]. In a chemically-induced bladder tumor model, treated animals showed 14.3% tumor incidence versus 60% in controls, alongside a twofold reduction in preneoplastic changes in bladder mucosa [10].

These effects appear mediated through immune enhancement and maintenance of cellular integrity rather than direct cytotoxicity toward tumor cells. Vilon also stimulates apoptosis in tissue cultures, suggesting it promotes programmed death of abnormal cells as part of normal tissue maintenance.

Two significant safety concerns emerge from this research domain. First, simultaneous combination with cyclophosphamide chemotherapy produced potential antagonism rather than additive benefit in one study, indicating that timing and sequencing of any combination approaches require careful investigation [11]. Second, one study in HER-2/neu transgenic mice reported increased mammary cancer incidence and shortened tumor development time in treated animals. This conflicting finding represents a critical safety flag that researchers must weigh against tumor-reduction findings in other models.

Key Research Highlights:

• Reduced spontaneous tumor incidence in aging mouse models
• 14.3% versus 60% tumor incidence in chemically-induced bladder tumor model
• Apoptosis stimulation in young and old tissue cultures
• Potential antagonism with cyclophosphamide; increased tumor incidence in one transgenic model

Cardiovascular Gene Expression Research

A DNA microarray study characterized Vilon’s effects on cardiac gene expression. Vilon alone altered expression patterns in 36 different cardiac genes. When combined with another peptide bioregulator, Epithalon, expression changes extended to more than 144 genes [13]. The cardiac genes affected include those involved in vascular regulation, hemodynamic function, coagulation pathways, and fibrinolysis. Vilon treatment increased concentrations of natural anticoagulants including antithrombin III and protein C, suggesting effects on clotting regulation relevant to cardiovascular research [13].

Key Research Highlights:

• Altered expression in 36 cardiac genes with Vilon treatment alone
• Expansion to 144-plus gene expression changes when combined with Epithalon
• Increased antithrombin III and protein C concentrations in treated models
• Potential relevance to coagulation pathway research

Renal Protection Research

Experimental chronic renal failure in rats treated with Vilon showed decreased serum transforming growth factor-beta-1 (TGF-beta-1) concentrations and reduced microvessel permeability in mesenteric circulation [14]. TGF-beta-1 drives fibrotic remodeling in kidney disease; its reduction suggests potential anti-fibrotic activity. These protective effects were observed two months after onset of experimental renal failure, indicating delayed but sustained impact on fibrotic processes [14].

Key Research Highlights:

• Decreased serum TGF-beta-1 in experimental chronic renal failure model
• Reduced microvessel permeability in mesenteric circulation
• Effects observed two months post-onset, suggesting sustained protective activity

Stress Response and Neuroendocrine Research

Vilon research includes investigation of stress response pathways. Studies report modulation of hypothalamic c-Fos expression, prevention of adrenal hypertrophy under stress conditions, and cortisol response modulation. These neuroendocrine findings suggest the peptide may influence the hypothalamic-pituitary-adrenal axis, though this research area is less developed than the immune and aging literature and the mechanistic basis for these effects remains unclear.

Gastrointestinal and Metabolic Applications

Preliminary research suggests Vilon enhances gut enzyme levels and improves glucose uptake in intestinal tissue, particularly in older subjects. Potential activation of intestinal stem cell proliferation in experimental models has also been reported. These metabolic applications represent an emerging area with limited published evidence compared to the immunological and aging literature.

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Subcutaneous administration has been confirmed as effective in multiple rodent studies, representing the primary delivery route in published Vilon research. Absorption following subcutaneous injection is presumed rapid given the small molecular size and hydrophilic nature of the compound. Oral activity has been suggested by gastrointestinal research findings, and the peptide’s reported resistance to gastric acid degradation is consistent with some level of oral bioavailability, but this has not been systematically characterized in pharmacokinetic studies.

Distribution and Metabolism

Tissue distribution studies indicate accumulation in lymphoid organs, specifically the thymus and spleen, which aligns with the immune-focused research findings. Nuclear localization has been observed in chromatin interaction studies, consistent with the proposed epigenetic mechanism. The amphipathic charge distribution of the lysine-glutamate structure, carrying both positive and negative charge regions, is hypothesized to facilitate both membrane permeability and nuclear access.

Plasma half-life has not been extensively characterized. Based on the dipeptide structure and general principles of peptide pharmacokinetics, rapid enzymatic clearance would be expected, likely within minutes to hours. This creates a notable gap: biological effects observed in animal studies extend for days to weeks following treatment, far beyond any plausible duration of parent peptide presence. Whether prolonged effects result from epigenetic modifications that persist after the peptide is cleared, from active metabolites, or from other mechanisms is unknown.

Delivery Methods Under Investigation

• Subcutaneous injection: Primary route used across published research; systemic distribution to lymphoid organs confirmed in animal models
• Oral administration: Suggested by gastrointestinal findings; stability in acidic conditions is consistent with partial oral bioavailability; not systematically studied
• Intraperitoneal injection: Used in some rodent study protocols for rapid systemic distribution

Excretion and Clearance

Standard dipeptide clearance through circulating peptidases and renal filtration is the expected elimination pathway. The small molecular weight of 275.30 g/mol would allow direct glomerular filtration without size-dependent barriers. Specific clearance rate data are not available in published literature. The disconnect between presumed rapid clearance and prolonged biological effects remains one of the most significant unexplained features of Vilon pharmacology.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

No human clinical trials for Vilon have been registered or published. The entire human-relevant evidence base consists of in vitro experiments on cultured lymphocytes from elderly donors. These cell culture findings, while mechanistically informative, cannot substitute for in vivo human pharmacokinetic or safety data. Safe and effective dosing in humans is entirely unknown.

Source and Replication Limitations

The overwhelming majority of published Vilon research originates from a single research group led by Professor Khavinson. Independent replication by unaffiliated laboratories in peer-reviewed English-language journals is extremely limited. The concentration of research within one group, with most publications in Russian-language journals, creates significant uncertainty about reproducibility and potential publication bias toward positive findings.

Mechanistic Resolution

Precise molecular targets through which Vilon interacts with chromatin have not been identified at atomic resolution. Direct DNA binding versus indirect engagement of chromatin-remodeling enzyme complexes has not been resolved experimentally. The selectivity for facultative rather than structural heterochromatin, while reported, has not been explained mechanistically. No membrane receptor has been identified.

Safety Concerns Requiring Investigation

The conflicting oncology finding in HER-2/neu transgenic mice, where Vilon treatment was associated with increased mammary cancer incidence and shortened tumor development time, is a significant safety concern that has not been resolved in subsequent research. The potential antagonism with cyclophosphamide chemotherapy adds further complexity for any combination research protocols.

Pharmacokinetic Gaps

Plasma half-life has not been measured. The relationship between presumed rapid peptide clearance and observed prolonged biological effects is unexplained. Metabolite identification and characterization have not been reported.

Areas Needing Further Investigation

• Independent replication by unaffiliated research groups across all major findings
• Human in vivo pharmacokinetic characterization: absorption, distribution, metabolism, and elimination
• Mechanistic resolution of chromatin interaction at atomic or molecular level
• Resolution of conflicting oncology findings, particularly the HER-2/neu transgenic mouse result
• Long-term safety assessment with chronic administration in diverse animal models
• Characterization of tissue-specific selectivity mechanisms

Regulatory and Research Status

Current Classification

FDA Status

Vilon is not approved by the FDA for human therapeutic use. No Investigational New Drug application for Vilon has been identified in public records. The compound is classified as a research chemical available for legitimate laboratory research under appropriate institutional oversight. The FDA has not issued specific guidance documents addressing Vilon.

WADA Status

Vilon does not appear on the current World Anti-Doping Agency prohibited list as a specifically named substance. However, WADA’s catch-all provisions for peptide hormones, growth factors, and related substances may apply. Researchers working with athletes subject to anti-doping regulations should consult current WADA documentation and seek appropriate guidance before any research protocols.

International Perspective

Russia and several Eastern European countries have a longer history of peptide bioregulator research and in some cases clinical investigation than Western jurisdictions, reflecting the origins of this compound class in Soviet-era science. However, Vilon is not approved as a therapeutic agent in any major Western regulatory jurisdiction including the EU and UK. The compound occupies a research chemical classification across international markets.

Research Community Approach

Legitimate Vilon research requires institutional review board oversight, appropriate biosafety protocols for peptide handling and administration, and compliance with applicable research regulations. Given the concentration of existing research in a single group, independent replication represents the highest-priority need for the field before further research investment. Any protocols involving human subjects would require extensive preclinical safety characterization that is currently absent from the published literature.

Future Research Directions

The most critical next steps for Vilon research are independent replication of major findings, systematic pharmacokinetic characterization in standard animal models, and resolution of the conflicting oncology data. If independent replication confirms the primary chromatin remodeling findings, the mechanistic novelty of epigenetic gene reactivation through a dipeptide would represent a compelling rationale for investment in safety characterization and eventual human pharmacokinetic studies.

Key Research Findings

Chromatin Architecture Restoration in Elderly Human Lymphocytes

Research Focus: Whether Vilon treatment could reverse age-related chromatin condensation in human immune cells Key Results: Differential scanning microcalorimetry of lymphocytes from elderly donors showed chromatin heat absorption patterns following Vilon treatment that resembled patterns from younger donors; ribosomal gene reactivation confirmed in NOR regions silenced by age-related heterochromatinization Significance: Provides direct human cell evidence for the proposed epigenetic mechanism and connects chromatin changes to functional outcomes including ribosomal biogenesis restoration Limitations: In vitro only; cultured cells do not replicate the complexity of in vivo immune aging; all work from one research group [1,2]

Lifespan Extension in Aging Mouse Model

Research Focus: Long-term effects of subcutaneous Vilon on lifespan and health parameters in female CBA mice Key Results: Increased mean lifespan versus age-matched untreated controls; enhanced physical activity and endurance; decreased core body temperature; reduced spontaneous neoplasm development; no adverse effects detected with chronic administration Significance: Demonstrates multi-parameter health improvement with lifespan extension in a mammalian model; absence of adverse effects with chronic use relevant to safety assessment Limitations: Single mouse strain and sex; not replicated independently; animal lifespan data has limited direct extrapolation to humans [6,7]

Chemically-Induced Bladder Tumor Prevention

Research Focus: Whether Vilon reduced tumor incidence in a chemically-induced bladder cancer model Key Results: 14.3% tumor incidence in treated animals versus 60% in controls; twofold reduction in preneoplastic changes in bladder mucosa Significance: Large effect size in a controlled carcinogenesis model suggests meaningful tumor-suppressive activity, potentially through immune enhancement mechanisms Limitations: Animal model only; mechanism not directly established; conflicting findings in transgenic cancer model complicate interpretation [10]

Thymic Restoration Following Gamma-Irradiation

Research Focus: Whether Vilon accelerated immune recovery after radiation-induced immunosuppression Key Results: Restored thymic lobule structure through cortical layer expansion; enhanced thymocyte proliferation and differentiation; normalized lymphocyte counts; improved B-cell and T-cell maturation Significance: Directly relevant to radiation biology applications; demonstrates functional immune restoration beyond simple cell count normalization Limitations: Rodent model; human immune recovery from radiation involves additional complexity not captured in these protocols [12]

Cardiac Gene Expression Profiling

Research Focus: Characterizing which cardiac genes are affected by Vilon using DNA microarray technology Key Results: Expression changes in 36 cardiac genes with Vilon alone; more than 144 genes affected when combined with Epithalon; increased concentrations of natural anticoagulants antithrombin III and protein C Significance: Demonstrates broad transcriptional effects beyond immune system and establishes relevance to cardiovascular gene expression research; microarray methodology provides genome-wide scope Limitations: Gene expression changes do not necessarily translate to functional cardiovascular outcomes; no functional cardiac endpoints reported; combination with Epithalon confounds Vilon-specific attribution [13]

Renal Fibrosis Modulation

Research Focus: Whether Vilon reduced fibrotic markers in experimental chronic renal failure Key Results: Decreased serum TGF-beta-1; reduced microvessel permeability in mesenteric circulation; protective effects present two months after onset of experimental renal failure Significance: TGF-beta-1 is a primary driver of kidney fibrosis; its reduction suggests potential utility in fibrotic disease research; delayed onset of effect suggests epigenetic rather than acute pharmacological mechanism Limitations: Experimental model of renal failure differs from human chronic kidney disease pathophysiology; mechanistic pathway not established [14]

Conflicting Oncology Data in Transgenic Model

Research Focus: Vilon effects in HER-2/neu transgenic mice with genetic predisposition to mammary cancer Key Results: Increased mammary cancer incidence and shortened tumor development time compared to untreated transgenic controls Significance: This finding directly contradicts tumor-prevention results from other models and represents the most important unresolved safety signal in the Vilon literature; researchers must weigh this finding against positive oncology data Limitations: Transgenic model may not be representative of naturally occurring cancer development; mechanism of apparent tumor promotion has not been investigated [9]

Frequently Asked Questions

What is Vilon and where does it come from?

Vilon is a synthetic dipeptide consisting of two amino acids, lysine and glutamic acid, making it one of the smallest known biologically active peptides. It was developed in the 1970s by Professor Vladimir Khavinson as part of a Soviet research program studying peptides derived from thymus tissue extracts. The goal was to identify the minimal amino acid sequences that retained the biological activity of longer thymic peptides.

What makes Vilon different from other research peptides?

Most research peptides work by binding to specific cell surface receptors and triggering signaling pathways. Vilon is studied primarily for a different mechanism: its proposed ability to interact directly with chromatin, the DNA-protein complex inside the cell nucleus that controls gene activity. Specifically, Vilon research focuses on whether it can reverse the progressive gene silencing that occurs with aging by reopening tightly condensed chromatin regions.

How much human research exists on Vilon?

Human clinical trial data does not exist for Vilon. The human-relevant evidence consists of laboratory experiments on immune cells cultured from elderly donors, where Vilon treatment produced changes in chromatin structure resembling younger cell patterns. All in vivo research has been conducted in animal models. This represents a major gap between the preclinical research base and any potential human application.

What are the biggest unanswered questions in Vilon research?

The most significant open questions include how a peptide with an expected rapid clearance from the bloodstream produces biological effects lasting days to weeks, which specific molecular targets Vilon interacts with inside the cell nucleus, and how to reconcile conflicting oncology findings across different cancer models. Independent replication of the major findings by research groups unaffiliated with the original developers is also a critical unmet need.

Is Vilon approved for any use?

Vilon is not approved for human therapeutic use by the FDA, EMA, or any other major regulatory agency. It is classified as a research chemical and is studied under laboratory conditions only. Any research involving Vilon requires appropriate institutional oversight and compliance with applicable regulations governing research chemical handling and use.

References

1. Lezhava, T., Monaselidze, J., Kadotani, T., Dvalishvili, N., & Buadze, T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News, 133, 111-115. PubMed

2. Khavinson, V.K., Lezhava, T.A., & Monaselidze, J.R. (2004). Peptide Lys-Glu activates chromatin remodeling in lymphocytes of elderly people. Bulletin of Experimental Biology and Medicine, 137(1), 78-81. PubMed

3. Khavinson, V.K., Mikhailova, O.N., Malinin, V.V., & Timofeeva, N.M. (2002). Effect of Vilon and Epithalon on expression of interleukin-2 in lymphocytes in aging. Bulletin of Experimental Biology and Medicine, 133(5), 496-499. PubMed

4. Khavinson, V.K., Linkova, N.S., Kvetnoy, I.M., & Polyakova, V.O. (2012). Peptide regulation of gene expression and protein synthesis in bone marrow cells. Bulletin of Experimental Biology and Medicine, 153(2), 288-291. PubMed

5. Lezhava, T., Monaselidze, J., Jokhadze, T., Dvalishvili, N., & Buadze, T. (2004). Influence of peptides Vilon and Epitalon on chromatin structure and functional activity in aging. Biogerontology, 5(2), 73-79. PubMed

6. Khavinson, V.K., Morozov, V.G., & Anisimov, V.N. (2000). Effect of vilon and epithalon on the life span and spontaneous tumor incidence in mice. Bulletin of Experimental Biology and Medicine, 130(7), 687-690. PubMed

7. Khavinson, V.K., & Anisimov, V.N. (2000). Peptide regulation of aging. Doklady Biological Sciences, 372, 261-263. PubMed

8. Lezhava, T., Monaselidze, J., Jokhadze, T., Buadze, T., & Dvalishvili, N. (2006). Reactivation of chromatin by peptide bioregulators in human aging lymphocytes. Georgian Medical News, 133, 111-115. PubMed

9. Anisimov, V.N., Khavinson, V.K., & Morozov, V.G. (1989). Twenty years of study on effects of pineal peptide preparation: Epithalamin in experimental gerontology and oncology. Annals of the New York Academy of Sciences, 719, 483-493. PubMed

10. Pliss, G.B., Khavinson, V.K., & Anisimov, V.N. (2001). Effect of Vilon on the incidence of N-nitrosobutyl(4-hydroxybutyl)amine-induced bladder tumors in rats. Bulletin of Experimental Biology and Medicine, 131(6), 558-560. PubMed

11. Anisimov, V.N., Khavinson, V.K., Alimova, I.N., Semchenko, A.V., & Yashin, A.I. (2002). Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic mice expressing her-2/neu oncogene. Bulletin of Experimental Biology and Medicine, 134(2), 187-190. PubMed

12. Khavinson, V.K., Malinin, V.V., Shataeva, L.K., & Panchenko, A.V. (2002). Vilon activates thymus recovery after radiation injury. Bulletin of Experimental Biology and Medicine, 134(2), 179-182. PubMed

13. Anisimov, V.N., Boheler, K.R., Khavinson, V.K., & Anisimov, S.V. (2002). Elucidation of effects of peptide Vilon on the expression of genes functionally active in the mouse heart using DNA microarray technology. Bulletin of Experimental Biology and Medicine, 133(3), 293-299. PubMed

14. Khavinson, V.K., Malinin, V.V., & Fedulov, A.S. (2005). Effect of vilon on the development of experimental chronic renal failure. Bulletin of Experimental Biology and Medicine, 140(3), 315-317. PubMed

15. Khavinson, V.K., Bondarev, I.E., & Butyugov, A.A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590-592. PubMed

16. Khavinson, V.K., Linkova, N.S., Butov, D.A., Baranova, E.V., Polyakova, V.O., & Kvetnoy, I.M. (2012). Relationship between clinical and immunological indices in elderly patients treated with the tetrapeptide Epithalon. Neuro Endocrinology Letters, 33(1), 65-71. PubMed

17. Morozov, V.G., & Khavinson, V.K. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology, 19(9-10), 501-505. PubMed

18. Anisimov, V.N., Khavinson, V.K., & Morozov, V.G. (1993). Carcinogenesis and aging. IV. Effect of low-molecular-weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and life span of C3H/Sn mice. Mechanisms of Ageing and Development, 19(3), 245-258. PubMed